This prospective cohort study aims to evaluate the prognostic significance of the C-reactive protein-to-albumin ratio (CAR), albumin-to-fibrinogen ratio (AFR), and serum ferritin level in newly diagnosed de novo non-M3 acute myeloid leukemia patients at Assiut University Hospitals.
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor clinical outcomes. Inflammatory and nutritional biomarkers such as the C-reactive protein-to-albumin ratio (CAR), albumin-to-fibrinogen ratio (AFR), and serum ferritin have shown potential prognostic value in various malignancies. This prospective single-center cohort study will include newly diagnosed de novo non-M3 AML patients aged 18 to 65 years. Baseline laboratory parameters including CRP, albumin, fibrinogen, and ferritin will be measured before induction chemotherapy. Patients will be followed for overall survival, event-free survival, and response to induction therapy. The study will assess the association of CAR, AFR, and serum ferritin with clinical outcomes.
Study Type
OBSERVATIONAL
Enrollment
208
Overall survival
Time from the date of AML diagnosis to death from any cause or last follow-up for surviving patients.
Time frame: Up to 24 months
Complete remission rate after induction chemotherapy
Proportion of patients achieving complete remission after induction chemotherapy, defined as bone marrow blasts less than 5%, absolute neutrophil count greater than 1.0 × 10⁹/L, platelet count greater than 100 × 10⁹/L, and independence from red cell transfusions.
Time frame: Day 28 after induction chemotherapy
Event-free survival
Time from diagnosis to the first occurrence of treatment failure, relapse, or death from any cause.
Time frame: Up to 24 months
Prognostic value of C-reactive protein-to-albumin ratio (CAR)
Hazard ratio for overall survival and event-free survival according to baseline C-reactive protein-to-albumin ratio (CAR), calculated as CRP (mg/L) divided by serum albumin (g/L), using Cox proportional hazards regression.
Time frame: Baseline and up to 24 months
Prognostic value of albumin-to-fibrinogen ratio (AFR)
Hazard ratio for overall survival and event-free survival according to baseline albumin-to-fibrinogen ratio (AFR), calculated as plasma fibrinogen concentration (g/L) divided by serum albumin concentration (g/L), using Cox proportional hazards regression.
Time frame: Baseline and up to 24 months
Prognostic value of serum ferritin
Hazard ratio for overall survival and event-free survival according to baseline serum ferritin level (ng/mL, corrected if CRP is elevated), using Cox proportional hazards regression.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Baseline and up to 24 months